BETHLEHEM, Pa.--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test, today issued a statement in support of the recent program announcement by the Centers for Disease Control and Prevention (“CDC”) that it has identified $35 million in additional funding to expand HIV testing and prevention programs. These funds are expected to be allocated to specific state and local jurisdictions by September 30, 2007 for utilization over the ensuing 12 months.
